MAP0004, a novel inhaled dihydroergotamine, is effective in the acute management of migraine, according to the results of the phase III FREEDOM-301 study (Aurora et al. Headache 2011; 51:507-517).
It takes 30 seconds or login using your email address
Please enter the email address that you registered the newsletter with
